90 related articles for article (PubMed ID: 24692146)
1. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
Salah-Eldin M; Abousamra NK; Azzam H
Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K; Miyamoto T; Eto T; Kamimura T; Taniguchi S; Okamura T; Ohtsuka E; Yoshida T; Higuchi M; Yoshimoto G; Fujisaki T; Abe Y; Takamatsu Y; Yokota S; Akashi K; Harada M
J Hematol Oncol; 2013 Feb; 6():14. PubMed ID: 23388549
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
Kim R; Bergugnat H; Pastoret C; Pasquier F; Raffoux E; Larcher L; Passet M; Grardel N; Delabesse E; Kubetzko S; Caye-Eude A; Meyer C; Marschalek R; Lafage-Pochitaloff M; Thiebaut-Bertrand A; Balsat M; Escoffre-Barbe M; Blum S; Baumann M; Banos A; Straetmans N; Gallego-Hernanz MP; Chalandon Y; Graux C; Soulier J; Leguay T; Hunault M; Huguet F; Lhéritier V; Dombret H; Boissel N; Clappier E
Blood; 2023 Nov; 142(21):1806-1817. PubMed ID: 37595275
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A; Henze G; Tsaur G; Budanov O; Roumiantseva J; Belevtsev M; Verzhbitskaya T; Movchan L; Lagoyko S; Zharikova L; Olshanskaya Y; Riger T; Valochnik A; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Aleinikova O; Fechina L; Karachunskiy A
Cancer Med; 2024 Apr; 13(8):e7172. PubMed ID: 38651186
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S; Madsen HO; Siitonen SM; Rosthøj S; Tierens A; Juvonen V; Osnes LTN; Vålerhaugen H; Hultdin M; Thörn I; Matuzeviciene R; Stoskus M; Marincevic M; Fogelstrand L; Lilleorg A; Toft N; Jónsson OG; Pruunsild K; Vaitkeviciene G; Vettenranta K; Lund B; Abrahamsson J; Schmiegelow K; Marquart HV
Leukemia; 2019 Jun; 33(6):1324-1336. PubMed ID: 30552401
[TBL] [Abstract][Full Text] [Related]
6. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
7. CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
Buldini B; Varotto E; Maurer-Granofszky M; Gaipa G; Schumich A; Brüggemann M; Mejstrikova E; Cazzaniga G; Hrusak O; Szczepanowski M; Scarparo P; Zimmermann M; Strehl S; Schinnerl D; Zaliova M; Karawajew L; Bourquin JP; Feuerstein T; Cario G; Alten J; Möricke A; Biffi A; Parasole R; Fagioli F; Valsecchi MG; Biondi A; Locatelli F; Attarbaschi A; Schrappe M; Conter V; Basso G; Dworzak MN
Blood; 2024 Apr; 143(17):1738-1751. PubMed ID: 38215390
[TBL] [Abstract][Full Text] [Related]
8. [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia].
Jia JS; Yang SM; Wang J; Jiang H; Zhao T; Bao L; Shi HX; Lu J; Zhu HH; Lai YY; Jiang B; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2016 Jun; 37(6):497-502. PubMed ID: 27431075
[TBL] [Abstract][Full Text] [Related]
9. Co-culture model of B-cell acute lymphoblastic leukemia recapitulates a transcription signature of chemotherapy-refractory minimal residual disease.
Rellick SL; Hu G; Piktel D; Martin KH; Geldenhuys WJ; Nair RR; Gibson LF
Sci Rep; 2021 Aug; 11(1):15840. PubMed ID: 34349149
[TBL] [Abstract][Full Text] [Related]
10. Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes.
Panda T; Rainchwar S; Singh R; Singh A; Soni M; Kakkar D; Jegan KR; Pillai RH; Palatty RJ; Jha K; Ahmed R; Halder R; Tejwani N; Panda D; Bhurani D; Agrawal N
Leuk Res; 2024 Jun; 141():107506. PubMed ID: 38663165
[TBL] [Abstract][Full Text] [Related]
11. Linkage of cell division cycle 42 with clinical features, treatment response and survival in adult Philadelphia chromosome negative acute lymphoblastic leukemia.
Chen Q; Zhu X; He D; Ding W
Scand J Clin Lab Invest; 2024 Apr; ():1-8. PubMed ID: 38662870
[TBL] [Abstract][Full Text] [Related]
12. Intracranial residual lesions following early intensification in a patient with T-cell acute lymphoblastic leukemia: a case report.
Nagamatsu Y; Isoda T; Inaji M; Oyama J; Niizato D; Tomomasa D; Mitsuiki N; Yamashita M; Kamiya T; Imai K; Kanegane H; Morio T; Takagi M
BMC Pediatr; 2024 May; 24(1):304. PubMed ID: 38704558
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment.
Hoster E; Pott C
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):437-445. PubMed ID: 27913513
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
Ferrero S; Dreyling M;
Haematologica; 2017 Jul; 102(7):1133-1136. PubMed ID: 28655809
[No Abstract] [Full Text] [Related]
15. Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes.
Chen Y; Chen Y; Wu Z; Li J; Huang Y; Peng X; Zheng J; Wu Y; Hu J
Ann Hematol; 2024 Mar; ():. PubMed ID: 38480542
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia chromosome-like B-acute lymphoblastic leukemia and disseminated juvenile xanthogranulomatosis with shared KRAS mutation.
Cheng J; Svoronos N; Pan M; Smith S; Vatsayan A; Jacobsohn D; Wistinghausen B
Pediatr Blood Cancer; 2024 Jun; 71(6):e30963. PubMed ID: 38523244
[No Abstract] [Full Text] [Related]
17. STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
Xu X; Huang Z; Ding C; Deng S; Ou J; Cai Z; Zhou Y; Liang H; Chen J; Wang Z; Liu X; Xuan L; Liu Q; Zheng Z; Li Z; Zhou H
Br J Haematol; 2024 Apr; ():. PubMed ID: 38639167
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction.
Li J; Lu A; Gao Y; Wan Y; Wang J; Zhang J; Hu T; Wu P; Chen X; Zou Y; Chen Y; Zhang L; Guo Y; Yang W; Li C; Zhang Y; Zhu X
Haematologica; 2024 May; ():. PubMed ID: 38695139
[TBL] [Abstract][Full Text] [Related]
19. Accurate identification of a precursor B-cell neoplasm.
Dikair A; Harper K; Leach M; Bain BJ
Am J Hematol; 2024 Apr; ():. PubMed ID: 38581168
[No Abstract] [Full Text] [Related]
20. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Beldjord K; Chevret S; Asnafi V; Huguet F; Boulland ML; Leguay T; Thomas X; Cayuela JM; Grardel N; Chalandon Y; Boissel N; Schaefer B; Delabesse E; Cavé H; Chevallier P; Buzyn A; Fest T; Reman O; Vernant JP; Lhéritier V; Béné MC; Lafage M; Macintyre E; Ifrah N; Dombret H;
Blood; 2014 Jun; 123(24):3739-49. PubMed ID: 24740809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
